Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study.

Fabio Salvatore MacalusoWalter FriesSara RennaAnna ViolaMarco MuscianisiMaria CappelloLaura GuidaSebastiano SiringoSalvatore CamilleriSerena GarufiAntonino Carlo PriviteraNunzio BelluardoEmiliano GiangrecoCarmelo BertolamiRoberto VassalloGiulia RizzutoRosalba OrlandoMarco VentimigliaAmbrogio Orlandonull null

Published in: United European gastroenterology journal (2020)

This study demonstrates the effectiveness and safety of VDZ as a first-line biological, particularly among elderly patients.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
patients with inflammatory bowel disease